Maze Therapeutics, a biopharmaceutical company, has commenced its Phase 1 clinical trial for MZE782, an oral small molecule therapy. MZE782 targets SLC6A19, a solute transporter, potentially benefiting approximately 5 million chronic kidney disease (CKD) patients in the United States who have limited responses to existing treatments.
Harold Bernstein, president and chief medical officer of Maze, highlighted that CKD impacts numerous individuals, and current therapies primarily aim to slow disease progression rather than addressing its underlying genetic causes. MZE782, developed using Maze’s Compass platform, seeks to replicate the protective effects of SLC6A19 variants.
The Phase 1 trial assesses safety, tolerability, pharmacokinetics, and pharmacodynamics. Non-invasive biomarkers will be utilized to optimize future clinical trial designs for patients. Initial findings, including potential proof of mechanism using these biomarkers, are anticipated in the second half of 2025.
Beyond its standalone potential, MZE782 may offer additional benefits when combined with standard-of-care treatments. It could complement existing regimens or be an alternative for patients who do not respond adequately to current therapies.
Maze Therapeutics harnesses human genetics to develop precision medicines for common renal, cardiovascular, and metabolic diseases. The company employs its Compass platform to uncover genetic variants associated with diseases and their underlying biological pathways in specific patient populations, driving its pipeline advancements.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
